Research
Energy balance
Patients experienced an average weight loss of 16.06 ± 7.6 pounds at 12 weeks and 38.82 ± 11.4 pounds at 24 weeks.
Practitioners can expect significant weight loss in patients using compounded GLP-1 ± GIP agonists.
StrongSupportsmedium confidence
The average weight loss observed at 12 weeks was 16.06 ± 7.6 pounds ( p = 0.001) and 38.82 ± 11.4 pounds at 24 weeks.
Why this rating
Based on the retrospective cohort study design with a clear outcome measure.
Source
Real‐world observations of using compounded <scp>GLP</scp> ‐1 ± <scp>GIP</scp> agonists within a clinical pharmacist‐managed cardiometabolic clinic
Shannon W. Finks et al. · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · 2025
cohort · n=50Cited 2×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →